Classifications: antineoplastic; hormone; anabolic steroid; Therapeutic: antineoplastic; anabolic steroid
Pregnancy Category: C
Controlled Substance: Schedule III
50 mg tablets
Chemotherapeutic agent with chemical configuration similar to certain androgens but devoid of androgenic activity (virilization)
in therapeutic doses. In breast cancer, effect may result from depression of ovarian function by inhibition of synthesis
of pituitary gonadotropin.
Effectiveness indicated by decrease in size of tumor; more than 50% of nonosseous lesions decrease in size even though
all bone lesions remain static.
Adjunctive treatment in palliation of breast carcinoma in postmenopausal women when hormone therapy is indicated. Also effective
in women diagnosed before menopause in whom ovarian function has been subsequently terminated.
Premenopausal women; breast cancer in males; pregnancy (category C), lactation.
Hypercalcemia; cardiorenal disease.
Route & Dosage
|Adjunctive Therapy for Breast Cancer
Adult: PO 250 mg q.i.d.
- Note: If anticoagulants are concurrently ordered, dose is usually reduced when testolactone is initiated.
- Store at 15°30° C (59°86° F) unless otherwise directed. Protect from freezing.
Adverse Effects (≥1%)CNS:
Deepening of the voice, acne
, facial hair growth, clitoral enlargement. GI:
Glossitis, anorexia; nausea, vomiting. CV:
Hypertension, edema in extremities.
Diagnostic Test Interference
Urinary 17-OHCS determinations may be elevated.
May enhance hypoprothrombinemic effects of oral anticoagulants
Readily from GI tract. Metabolism:
In liver. Elimination:
Assessment & Drug Effects
- Monitor therapeutic effectiveness. Clinical response usually occurs in 612 wk.
- Lab tests: Check plasma calcium levels periodically (normal serum calcium: 8.510.6 mg/dL).
- Monitor PT and INR carefully with concurrent anticoagulant therapy.
- Report S&S that suggest impending hypercalcemia (see Appendix F).
- Monitor I&O ratio and pattern.
- Encourage patient mobility if feasible; if not, assist with passive exercises.
Patient & Family Education
- Drug treatment is usually continued for a minimum of 3 mo to evaluate response (unless there is active progression of the
- Be aware that hypercalcemia represents active remission of bone metastasis; if it occurs, appropriate therapy is instituted.